Trial reportJMIR mHealth and uHealth2024
Conversational Chatbot for Cigarette Smoking Cessation: Results From the 11-Step User-Centered Design Development Process and Randomized Controlled Trial.
Trial report in JMIR mHealth and uHealth, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03585231 (Say "Hello" To Your Digital Coach), which is not on this map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Say "Hello" To Your Digital Coach: Development and Pilot Trial of the First Conversational Agent for Smoking Cessation
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- LLM-assisted systematic review of large language models in clinical medicine.Nature medicine · 2026Pooled it
- The Effectiveness of AI Chatbots in Alleviating Mental Distress and Promoting Health Behaviors Among Adolescents and Young Adults: Systematic Review and Meta-Analysis.Journal of medical Internet research · 2025Pooled it
- The Analytical Framework of Clinical Trials Evaluating Clinical Outcomes of Artificial Intelligence-Based Digital Health Interventions: A Systematic Literature Review.Journal of market access & health policy · 2026Review
- Tailored personas for anticipatory grief management among primary family caregivers of patients with advanced lung cancer in China: a qualitative study.Scientific reports · 2026Article
- Enhancing Detection of Message Intents in a Mobile Health Smoking-Cessation Intervention Using Large Language Model Fine-Tuning, Data Downsampling, and Error Correction: Algorithm Development and Validation.Journal of medical Internet research · 2026Article
- Engaging Artificial Intelligence (AI)-based chatbots in digital health: A systematic review.PLOS digital health · 2026Article
- Functional experiences of a LINE-based chatbot and their associations with system use experience among older adults: a cross-sectional study.Frontiers in public health · 2026Article
- AI-Enabled Personalized Smoking Cessation Intervention With the Aipaca Chatbot: Mixed Methods Feasibility Study.JMIR formative research · 2025Observational
- Metformin-Enhanced Digital Therapeutics for the Affordable Primary Prevention of Diabetes and Cardiovascular Diseases: Advancing Low-Cost Solutions for Lifestyle-Related Chronic Disorders.Healthcare (Basel, Switzerland) · 2025Article
- ChatGPT-Based Chatbot for Help Quitting Smoking via Text Messaging: An Interventional Study.JMIR formative research · 2025Article
- Assessing the Adherence of ChatGPT Chatbots to Public Health Guidelines for Smoking Cessation: Content Analysis.Journal of medical Internet research · 2025Article
- Review
- Efficacy of a conversational chatbot for cigarette smoking cessation: Protocol of the QuitBot full-scale randomized controlled trial.Contemporary clinical trials · 2024Article
- Overcoming Challenges to Remote Biochemical Verification of Smoking Status: Insights From Participant Interviews.Substance use : research and treatmentArticle
- How to design digital health interventions with artificial intelligence: A scoping review.Digital healthReview
- Smoking Cessation in Primary Care: A Narrative Review of Evidence-Based Treatment, Emerging Technology, and Harm Reduction Approaches.Journal of primary care & community healthReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundConversational chatbots are an emerging digital intervention for smoking cessation. No studies have reported on the entire development process of a cessation chatbot.
objectiveWe aim to report results of the user-centered design development process and randomized controlled trial for a novel and comprehensive quit smoking conversational chatbot called QuitBot.
methodsThe 4 years of formative research for developing QuitBot followed an 11-step process: (1) specifying a conceptual model; (2) conducting content analysis of existing interventions (63 hours of intervention transcripts); (3) assessing user needs; (4) developing the chat's persona ("personality"); (5) prototyping content and persona; (6) developing full functionality; (7) programming the QuitBot; (8) conducting a diary study; (9) conducting a pilot randomized controlled trial (RCT); (10) reviewing results of the RCT; and (11) adding a free-form question and answer (QnA) function, based on user feedback from pilot RCT results. The process of adding a QnA function itself involved a three-step process: (1) generating QnA pairs, (2) fine-tuning large language models (LLMs) on QnA pairs, and (3) evaluating the LLM outputs.
resultsWe developed a quit smoking program spanning 42 days of 2- to 3-minute conversations covering topics ranging from motivations to quit, setting a quit date, choosing Food and Drug Administration-approved cessation medications, coping with triggers, and recovering from lapses and relapses. In a pilot RCT with 96% three-month outcome data retention, QuitBot demonstrated high user engagement and promising cessation rates compared to the National Cancer Institute's SmokefreeTXT text messaging program, particularly among those who viewed all 42 days of program content: 30-day, complete-case, point prevalence abstinence rates at 3-month follow-up were 63% (39/62) for QuitBot versus 38.5% (45/117) for SmokefreeTXT (odds ratio 2.58, 95% CI 1.34-4.99; P=.005). However, Facebook Messenger intermittently blocked participants' access to QuitBot, so we transitioned from Facebook Messenger to a stand-alone smartphone app as the communication channel. Participants' frustration with QuitBot's inability to answer their open-ended questions led to us develop a core conversational feature, enabling users to ask open-ended questions about quitting cigarette smoking and for the QuitBot to respond with accurate and professional answers. To support this functionality, we developed a library of 11,000 QnA pairs on topics associated with quitting cigarette smoking. Model testing results showed that Microsoft's Azure-based QnA maker effectively handled questions that matched our library of 11,000 QnA pairs. A fine-tuned, contextualized GPT-3.5 (OpenAI) responds to questions that are not within our library of QnA pairs.
conclusionsThe development process yielded the first LLM-based quit smoking program delivered as a conversational chatbot. Iterative testing led to significant enhancements, including improvements to the delivery channel. A pivotal addition was the inclusion of a core LLM-supported conversational feature allowing users to ask open-ended questions.
trial registrationClinicalTrials.gov NCT03585231; https://clinicaltrials.gov/study/NCT03585231.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.